论文部分内容阅读
目的 探讨结肠良恶性病变C erbB 2和PCNA表达及临床意义。方法 应用免疫组织化学的方法 (S P法 )检测 6 4例结肠癌和 44例结肠良性病变的C erbB 2癌基因产物和PCNA的表达情况。结果 C erbB 2和PCNA在结肠癌、结肠腺瘤和正常肠粘膜的阳性表达率分别为 5 3 12 % (34 6 4)、2 0 .0 0 % (4 2 0 )、16 .6 6 % (4 2 4)和 71.87% (46 6 4)、5 0 0 0 % (10 2 0 )、33.33% (8 2 4)。其中C erbB 2的表达在结肠癌与腺瘤及正常肠粘膜间均有极显著差异 (P <0 0 1) ;PCNA在结肠癌与结肠腺瘤间无显著差异 (P >0 0 5 ) ,与正常肠粘膜有极显著差异P <0 0 1)。C erbB 2和PCNA在合并后的Dukes分期 (A、B与C、D期 )中的阳性表达率分别为 34 .6 1% (9 2 6 )、6 5 .78% (2 5 38)和 5 3.84% (14 2 6 )、84.2 1%(32 38) ,差异均有显著意义 (P分别 <0 0 5和 <0 0 1)。C erbB 2和PCNA的表达呈显著正相关关系 (P <0 .0 1)。结论 C erbB 2和PCNA在结肠癌和腺瘤恶变的发生和发展中发挥重要作用 ,其免疫组化测定将有助于结肠良恶性病变的鉴别诊断和临床分期。
Objective To investigate the expression of C erbB 2 and PCNA in benign and malignant colonic lesions and its clinical significance. Methods The expression of C erbB 2 oncogene products and PCNA in 64 cases of colon cancer and 44 cases of benign colon benign lesions were detected by immunohistochemistry (S P method). Results The positive rates of C erbB 2 and PCNA in colon cancer, colon adenoma and normal intestinal mucosa were 53 12% (34 6 4), 20 0% (4 20), 16 6 6% (4 2 4) and 71.87% (46 6 4), 5 0 0 0% (10 2 0) and 33.33% (8 2 4) respectively. Among them, the expression of C erbB 2 was significantly different between colon cancer and adenoma and normal intestinal mucosa (P <0.01); PCNA had no significant difference between colon cancer and colon adenoma (P> 0.05) Significantly different from normal intestinal mucosa (P <0.01). The positive rates of C erbB 2 and PCNA in the combined Dukes stage (A, B and C, D stages) were 34.61% (9 2 6), 65.78% (2 5 38) and 5 3.84% (14 2 6), 84.2 1% (32 38) respectively. The difference was significant (P <0 05 and <0 01, respectively). There was a significant positive correlation between C erbB 2 and PCNA expression (P <0.01). Conclusions C erbB 2 and PCNA play an important role in the carcinogenesis and progression of colorectal carcinoma and adenoma. Immunohistochemical detection of C erbB 2 and PCNA will be helpful for the differential diagnosis and clinical staging of benign and malignant colonic lesions.